The IPO Buzz: Generate Biomedicines (GENB Proposed) Launches $400 Million IPO
Generate Biomedicines, Inc. (GENB Proposed), a clinical biology company developing a treatment for severe asthma, launched its $400 million IPO early today – Monday, Feb. 23, 2026 – for pricing later this week. (Please see the IPO Calendar for the pricing date.) In its S-1/A filing, Generate Biomedicines disclosed the IPO’s terms – 25 million […]
February 23, 2026 Read More